

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Confirmation No. 6122

KONIECZNA et al.

Atty. Ref.: 37-86

Serial No. 10/564,148

T.C. / Art Unit: 1618

Filed: November 9, 2006

Examiner: J.M. Vu

FOR: PHARMACEUTICAL FORMULATION COMPRISING LEVOTHYROXINE

* * *

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97(d)

April 19, 2011

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Attached is Form PTO-1449 listing two patent documents, which were first cited in a recent Office Action for a counterpart Japanese patent application. The undersigned certifies under 37 CFR § 1.97(e):

“[E]ach item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.”

The fee required under 37 CFR § 1.97(c) is also filed herewith. But should that fee be missing or inadequate, charge the deficiency to our Deposit Account No. 14-1140 under Order No. 37-86. Therefore, the requirements for filing an Information Disclosure Statement (IDS) after receipt of a Notice of Allowance are satisfied.

Besides their English-language abstracts, translations of their pertinent parts are attached for the Examiner's consideration. JP 2001-064177 (appearing to correspond to WO 01/12193) was alleged to describe examples using pregelatinised starch as disin-

tegrant in combination with magnesium stearate as a lubricant (see claims 8 and 10 and Table 3 on page 12 of WO 01/12193, which is attached). JP 2001-163770 was alleged to describe pregelatinised starch as a disintegrant equivalent to croscarmellose sodium (see paragraph [0014] and Table 5 in paragraph [0045], which are attached).

This IDS is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect is earnestly solicited, along with additional time under 37 CFR § 1.97(f), to enable Applicants to comply fully. In particular, if any of the listed documents are missing or incomplete, please contact the undersigned who will provide another copy.

As provided by 37 CFR §§ 1.97(g) and (h), no inference should be made that this information and the listed documents are prior art merely because they have been submitted for consideration. Further, no representation is being made that a search has been conducted or that this statement encompasses all possible material information.

Consideration of the foregoing and enclosures, as well as return of an initialed copy of the form per M.P.E.P. § 609 to confirm consideration of the listed documents, are earnestly solicited. The Examiner is invited to contact the undersigned if any further information is needed.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: /Gary R. Tanigawa/
Gary R. Tanigawa
Reg. No. 43,180

901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100